568 related articles for article (PubMed ID: 26051506)
41. Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
Moreau P; Facon T; Touzeau C; Benboubker L; Delain M; Badamo-Dotzis J; Phelps C; Doty C; Smit H; Fourneau N; Forslund A; Hellemans P; Leleu X
Leuk Lymphoma; 2016 Jul; 57(7):1546-59. PubMed ID: 26758913
[TBL] [Abstract][Full Text] [Related]
42. Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Cavenagh JD; Popat R
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):501-507. PubMed ID: 29804873
[TBL] [Abstract][Full Text] [Related]
43. Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
Pan D; Mouhieddine TH; Upadhyay R; Casasanta N; Lee A; Zubizarreta N; Moshier E; Richter J
Semin Oncol; 2023; 50(1-2):40-48. PubMed ID: 37005144
[TBL] [Abstract][Full Text] [Related]
44. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
Stegmann DA
Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
[TBL] [Abstract][Full Text] [Related]
45. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
46. Panobinostat: a review of trial results and future prospects in multiple myeloma.
Libby EN; Becker PS; Burwick N; Green DJ; Holmberg L; Bensinger WI
Expert Rev Hematol; 2015 Feb; 8(1):9-18. PubMed ID: 25410127
[TBL] [Abstract][Full Text] [Related]
47. NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments.
Hall CJ; Doss S; Hay N; Sutcliffe F; Stevens A
Lancet Oncol; 2016 Mar; 17(3):279-80. PubMed ID: 26827243
[No Abstract] [Full Text] [Related]
48. Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD).
Sekiguchi Y; Takizawa H; Inano T; Fukuda Y; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Hematol; 2017 Oct; 106(4):581-587. PubMed ID: 28353192
[TBL] [Abstract][Full Text] [Related]
49. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
[TBL] [Abstract][Full Text] [Related]
50. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
Berdeja JG; Hart LL; Mace JR; Arrowsmith ER; Essell JH; Owera RS; Hainsworth JD; Flinn IW
Haematologica; 2015 May; 100(5):670-6. PubMed ID: 25710456
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.
Liu JD; Sun CY; Tang L; Wu YY; Wang QY; Hu B; Hu Y
Sci Rep; 2016 Jun; 6():27361. PubMed ID: 27270478
[TBL] [Abstract][Full Text] [Related]
52. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
53. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
[TBL] [Abstract][Full Text] [Related]
54. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
[TBL] [Abstract][Full Text] [Related]
55. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
56. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599
[TBL] [Abstract][Full Text] [Related]
57. Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Br J Haematol; 2019 May; 185(3):573-578. PubMed ID: 30125960
[No Abstract] [Full Text] [Related]
58. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
59. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
60. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
Ghobrial IM; Campigotto F; Murphy TJ; Boswell EN; Banwait R; Azab F; Chuma S; Kunsman J; Donovan A; Masood F; Warren D; Rodig S; Anderson KC; Richardson PG; Weller E; Matous J
Blood; 2013 Feb; 121(8):1296-303. PubMed ID: 23287861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
